A randomized trial of three renal transplant induction antibodies: Early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring

Gaetano Ciancio, George W Burke, Jeffrey Gaynor, Manuel R. Carreno, Robert E. Cirocco, James M. Mathew, Adela D Mattiazzi, Tatiana Cordovilla, David Roth, Warren Kupin, Anne Rosen, Violet Esquenazi, Andreas G. Tzakis, Joshua Miller

Research output: Contribution to journalArticle

176 Scopus citations


Background. New trends in immunosuppression in clinical transplantation include the use of antibody induction agents in protocols that emphasize reduction or avoidance of steroids and calcineurin inhibitors. Methods. In a randomized trial using three different antibody induction agents in 90 first renal transplant recipients from cadaver donors, group A received Thymoglobulin, group B received Alemtuzumab, and group C received Daclizumab. Maintenance immunosuppression included tacrolimus and mycophenolate in all three arms, and methylprednisolone in groups A and C only (standard clinical institutional practice). The targeted trough level of tacrolimus was between 8 and 10 ng/mL for groups A and C, respectively, with a targeted mycophenolate dose of 1 g twice daily. However, in group B, the target tacrolimus trough level was 4 to 7 ng/mL to reduce long-term nephrotoxicity, with 500 mg twice-daily doses of mycophenolate, without steroid maintenance. Results. In this 15-month median postoperative interval report, there were no notable differences in demographics and patient and graft survivals. Acute rejection rates at 1 year were equivalent, that is, 5 of 30 in all three groups (16.6%). In group B, there was slightly lower renal function at 1 month, but no difference at 1 year. There was also significantly more leukopenia, but a greater percentage of T-regulatory cells and number of Fox-P3 mRNA copies by flow cytometry and semiquantitative polymerase chain reaction analysis, respectively, in group B. Conclusions. This preliminary analysis indicates that 80% of the patients in group B remained steroid-free 1 year postoperatively, with lower tacrolimus trough levels and no difference in other adverse events.

Original languageEnglish
Pages (from-to)457-465
Number of pages9
Issue number4
StatePublished - Aug 27 2005



  • Adverse events
  • Alemtuzumab
  • Campath-1H
  • Daclizumab
  • Graft survival
  • Thymoglobulin

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this